ZA987817B - A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist - Google Patents

A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist

Info

Publication number
ZA987817B
ZA987817B ZA987817A ZA987817A ZA987817B ZA 987817 B ZA987817 B ZA 987817B ZA 987817 A ZA987817 A ZA 987817A ZA 987817 A ZA987817 A ZA 987817A ZA 987817 B ZA987817 B ZA 987817B
Authority
ZA
South Africa
Prior art keywords
combination
reuptake inhibitor
partial agonist
ht1b antagonist
ht1b
Prior art date
Application number
ZA987817A
Other languages
English (en)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA987817B publication Critical patent/ZA987817B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
ZA987817A 1997-09-18 1998-08-27 A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist ZA987817B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (1)

Publication Number Publication Date
ZA987817B true ZA987817B (en) 1999-03-18

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA987817A ZA987817B (en) 1997-09-18 1998-08-27 A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist

Country Status (30)

Country Link
US (1) US6159971A (no)
EP (1) EP1014985B1 (no)
JP (1) JP2001516718A (no)
KR (1) KR20010024076A (no)
CN (1) CN1195519C (no)
AR (1) AR015448A1 (no)
AT (1) ATE240733T1 (no)
AU (1) AU752722B2 (no)
BR (1) BR9812088A (no)
CA (1) CA2302382A1 (no)
DE (1) DE69814882T2 (no)
DK (1) DK1014985T3 (no)
EE (1) EE04141B1 (no)
ES (1) ES2200370T3 (no)
HK (1) HK1032739A1 (no)
HU (1) HUP0200602A3 (no)
IL (1) IL134776A0 (no)
IS (1) IS5406A (no)
MY (1) MY116280A (no)
NO (1) NO20001399L (no)
NZ (1) NZ503171A (no)
PL (1) PL339371A1 (no)
PT (1) PT1014985E (no)
RU (1) RU2214824C2 (no)
SE (1) SE9703375D0 (no)
SK (1) SK2852000A3 (no)
TR (1) TR200000727T2 (no)
TW (1) TW589183B (no)
WO (1) WO1999013877A1 (no)
ZA (1) ZA987817B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (en) * 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
DE60231507D1 (de) * 2001-07-20 2010-07-01 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
US20060217394A1 (en) * 2005-02-23 2006-09-28 Silvan S. Tomkins Institute, Inc. Treatment of anhedonia
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ATE204262T1 (de) * 1991-09-18 2001-09-15 Glaxo Group Ltd Benzanilidderivate als 5-ht1d-antagonisten
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
EP1014985A1 (en) 2000-07-05
PT1014985E (pt) 2003-10-31
EP1014985B1 (en) 2003-05-21
NZ503171A (en) 2002-02-01
AU752722B2 (en) 2002-09-26
EE04141B1 (et) 2003-10-15
KR20010024076A (ko) 2001-03-26
DE69814882T2 (de) 2004-05-19
NO20001399D0 (no) 2000-03-17
NO20001399L (no) 2000-05-10
MY116280A (en) 2003-12-31
TW589183B (en) 2004-06-01
CA2302382A1 (en) 1999-03-25
JP2001516718A (ja) 2001-10-02
DK1014985T3 (da) 2003-09-15
ATE240733T1 (de) 2003-06-15
TR200000727T2 (tr) 2000-09-21
HUP0200602A3 (en) 2003-04-28
CN1278729A (zh) 2001-01-03
IS5406A (is) 2000-03-15
HUP0200602A2 (hu) 2002-07-29
SK2852000A3 (en) 2000-09-12
US6159971A (en) 2000-12-12
BR9812088A (pt) 2000-09-26
EE200000141A (et) 2001-02-15
HK1032739A1 (en) 2001-08-03
IL134776A0 (en) 2001-04-30
CN1195519C (zh) 2005-04-06
PL339371A1 (en) 2000-12-18
DE69814882D1 (de) 2003-06-26
RU2214824C2 (ru) 2003-10-27
ES2200370T3 (es) 2004-03-01
WO1999013877A1 (en) 1999-03-25
SE9703375D0 (sv) 1997-09-18
AU9193098A (en) 1999-04-05
AR015448A1 (es) 2001-05-02

Similar Documents

Publication Publication Date Title
ZA987817B (en) A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist
HUP0203586A3 (en) The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
HUP0103408A3 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
HK1124339A1 (en) 20-keto-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal activity 20--11-
EP1009415A4 (en) INHIBITORS OF $ g (b) -LACTAMASES AND THEIR USES
AU2407997A (en) Combined use of gnrh agonist and antagonist
IL134775A0 (en) A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
IL140328A0 (en) Inhibitors of transcription factor nf-kb
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
IL117988A0 (en) A new combination of an inhibitor and an antagonist
SI0736525T1 (en) Benzonitriles as 5-HT agonists and antagonists
PL330195A1 (en) Antagonist of dopamine d4 receptor
ZA9810272B (en) Formulation of a cobination of a opioid and a alpha-adrenergic agonist and the use thereof
AU1193199A (en) Arylpiperazines as serotonin reuptake inhibitors and 5-ht1dalpha antagonists
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
IL134774A0 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
SI1014985T1 (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
GB9700233D0 (en) Use of glycosidase inhibitors
SI1021183T1 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
AU3148500A (en) Scale and corrosion inhibitor
SI0822813T1 (en) A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a antagonist
GB9600736D0 (en) Corrosion and scale inhibitors